Here we sought to explore whether the retrotranscriptase inhibitor 3TC prevents tau pathology in a tauopathy mouse model based on the overexpression of human tau with a mutation present in patients with frontotemporal dementia with parkinsonism-17 (FTDP-17) and whether tau alters retrotransposon levels. Here, MAPT is linked to tauopathy.